Openbookopenbook
Equity
PGEN
+0.0 · +0.00%
USD · NASDAQ

Precigen Inc(PGEN) Stock Analysis | Healthcare

USD --+0.00%
Reward42Moderate
Risk61Medium-High
75%Data
Thin -184% profit margin · Revenue growing 6323% YoY
Value Trap
Market Cap:2.49Bn
ⓘ
Reward Rating
42
Moderate
Reward Assessment
75% data coverage
Bottom 10% of stocksView factors
ⓘ
Risk Rating
61
Medium-High
Risk Assessment
7 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on PGEN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for PGEN, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $14.50.

What is Precigen Inc?

,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

PGEN · Verdict

Moderate reward · elevated risk

PGEN's standout is valuation; cash flow and profitability weigh on the picture.

Based on 88% data coverage

PGEN · Verdict

What’s working & what to watch

Strengths 1

  • Valuation71/100

    P/E 51.3× · PEG 0.24

Watchouts 4

  • Cash flow6/100

    -928% free-cash-flow margin

  • Profitability9/100

    -2588% net margin · -837% ROE

  • Balance sheet30/100

    Current ratio 3.09

  • Growth42/100

    Revenue -28.9% CAGR

Model-based scoring. For information only — not financial advice.

What is Precigen Inc?

,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.49B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (42)

The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

NKTRMid Cap / 2.5B market cap
Nektar Therapeutics
Compare
VRDNMid Cap / 2.5B market cap
Viridian Therapeutics Inc
Compare
PHVSMid Cap / 2.5B market cap
Pharvaris BV
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap2.49B
P/E RatioN/A
Dividend YieldN/A
Beta1.009
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
14,772,781 shares
$15.8M
0
6-9months
11,900,036 shares
$7.9M
0
9-12months
89,950,572 shares
$37.7M
428,216 shares
$116k
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.